IBDEI30E ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,48054,0)
 ;;=E86.0^^185^2417^4
 ;;^UTILITY(U,$J,358.3,48054,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,48054,1,3,0)
 ;;=3^Dehydration
 ;;^UTILITY(U,$J,358.3,48054,1,4,0)
 ;;=4^E86.0
 ;;^UTILITY(U,$J,358.3,48054,2)
 ;;=^332743
 ;;^UTILITY(U,$J,358.3,48055,0)
 ;;=Z86.31^^185^2417^100
 ;;^UTILITY(U,$J,358.3,48055,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,48055,1,3,0)
 ;;=3^Personal Hx of Diabetic Foot Ulcer
 ;;^UTILITY(U,$J,358.3,48055,1,4,0)
 ;;=4^Z86.31
 ;;^UTILITY(U,$J,358.3,48055,2)
 ;;=^5063467
 ;;^UTILITY(U,$J,358.3,48056,0)
 ;;=E10.8^^185^2417^5
 ;;^UTILITY(U,$J,358.3,48056,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,48056,1,3,0)
 ;;=3^Diabetes Type 1 w/ Unspec Complications
 ;;^UTILITY(U,$J,358.3,48056,1,4,0)
 ;;=4^E10.8
 ;;^UTILITY(U,$J,358.3,48056,2)
 ;;=^5002625
 ;;^UTILITY(U,$J,358.3,48057,0)
 ;;=E10.9^^185^2417^6
 ;;^UTILITY(U,$J,358.3,48057,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,48057,1,3,0)
 ;;=3^Diabetes Type 1 w/o Complications
 ;;^UTILITY(U,$J,358.3,48057,1,4,0)
 ;;=4^E10.9
 ;;^UTILITY(U,$J,358.3,48057,2)
 ;;=^5002626
 ;;^UTILITY(U,$J,358.3,48058,0)
 ;;=E11.40^^185^2417^15
 ;;^UTILITY(U,$J,358.3,48058,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,48058,1,3,0)
 ;;=3^Diabetes Type 2 w/ Diabetic Neuropathy,Unspec
 ;;^UTILITY(U,$J,358.3,48058,1,4,0)
 ;;=4^E11.40
 ;;^UTILITY(U,$J,358.3,48058,2)
 ;;=^5002644
 ;;^UTILITY(U,$J,358.3,48059,0)
 ;;=E11.620^^185^2417^11
 ;;^UTILITY(U,$J,358.3,48059,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,48059,1,3,0)
 ;;=3^Diabetes Type 2 w/ Diabetic Dermatitis
 ;;^UTILITY(U,$J,358.3,48059,1,4,0)
 ;;=4^E11.620
 ;;^UTILITY(U,$J,358.3,48059,2)
 ;;=^5002655
 ;;^UTILITY(U,$J,358.3,48060,0)
 ;;=E11.610^^185^2417^14
 ;;^UTILITY(U,$J,358.3,48060,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,48060,1,3,0)
 ;;=3^Diabetes Type 2 w/ Diabetic Neuropathic Arthropathy
 ;;^UTILITY(U,$J,358.3,48060,1,4,0)
 ;;=4^E11.610
 ;;^UTILITY(U,$J,358.3,48060,2)
 ;;=^5002653
 ;;^UTILITY(U,$J,358.3,48061,0)
 ;;=E11.52^^185^2417^17
 ;;^UTILITY(U,$J,358.3,48061,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,48061,1,3,0)
 ;;=3^Diabetes Type 2 w/ Diabetic Periph Angiopathy w/ Gangrene
 ;;^UTILITY(U,$J,358.3,48061,1,4,0)
 ;;=4^E11.52
 ;;^UTILITY(U,$J,358.3,48061,2)
 ;;=^5002651
 ;;^UTILITY(U,$J,358.3,48062,0)
 ;;=E11.51^^185^2417^18
 ;;^UTILITY(U,$J,358.3,48062,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,48062,1,3,0)
 ;;=3^Diabetes Type 2 w/ Diabetic Periph Angiopathy w/o Gangrene
 ;;^UTILITY(U,$J,358.3,48062,1,4,0)
 ;;=4^E11.51
 ;;^UTILITY(U,$J,358.3,48062,2)
 ;;=^5002650
 ;;^UTILITY(U,$J,358.3,48063,0)
 ;;=E11.621^^185^2417^19
 ;;^UTILITY(U,$J,358.3,48063,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,48063,1,3,0)
 ;;=3^Diabetes Type 2 w/ Foot Ulcer
 ;;^UTILITY(U,$J,358.3,48063,1,4,0)
 ;;=4^E11.621
 ;;^UTILITY(U,$J,358.3,48063,2)
 ;;=^5002656
 ;;^UTILITY(U,$J,358.3,48064,0)
 ;;=E11.44^^185^2417^8
 ;;^UTILITY(U,$J,358.3,48064,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,48064,1,3,0)
 ;;=3^Diabetes Type 2 w/ Diabetic Amyotrophy
 ;;^UTILITY(U,$J,358.3,48064,1,4,0)
 ;;=4^E11.44
 ;;^UTILITY(U,$J,358.3,48064,2)
 ;;=^5002648
 ;;^UTILITY(U,$J,358.3,48065,0)
 ;;=E11.59^^185^2417^7
 ;;^UTILITY(U,$J,358.3,48065,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,48065,1,3,0)
 ;;=3^Diabetes Type 2 w/ Circulatory Complications
 ;;^UTILITY(U,$J,358.3,48065,1,4,0)
 ;;=4^E11.59
 ;;^UTILITY(U,$J,358.3,48065,2)
 ;;=^5002652
